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Public payers around the world are increasingly using cost-
effectiveness thresholds (CETs) to assess the value-for-money of an 
intervention and make coverage decisions. However, there is still 
much confusion about the meaning and uses of the CET, how it 
should be calculated, and what constitutes an adequate evidence base 
for its formulation. One widely referenced and used threshold in the 
last decade has been the 1-3 GDP per capita, which is often attributed 
to the Commission on Macroeconomics and  WHO guidelines on 
Choosing Interventions that are Cost Effective (WHO-CHOICE). For 
many reasons, however, this threshold has been widely criticised; 
which has led experts across the world, including the WHO, to 
discourage its use. This has left a vacuum for policy-makers and 
technical staff at a time when countries are wanting to move towards 
Universal Health Coverage.  
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This article seeks to address this gap by offering five practical options 
for decision-makers in low- and middle-income countries that can be 
used instead of the 1-3 GDP rule, to combine existing evidence with 
fair decision-rules or develop locally relevant CETs. It builds on 
existing literature as well as an engagement with a group of experts 
and decision-makers working in low, middle and high income 
countries.
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Introduction
Public payers around the world are increasingly using Health 
Technology Assessment (HTA) to inform resource allocation 
decisions (Leech et al., 2018; MacQuilkan et al., 2018; Tantivess 
et al., 2017; World Health Organization, 2015). These decisions 
are often based on evidence of the expected additional interven-
tion costs and health benefits summarized as the incremental 
cost-effectiveness ratio (ICER). This is a measure of the value 
of resources that are actually needed in a specific location and at 
a specific time to produce one unit of health (most commonly a 
Quality Adjusted Life Year – QALY- or a Disability Adjusted Life 
Year – DALY averted). ICERs can be used to compare compet-
ing interventions or can be evaluated against a pre-defined deci-
sion rule referred to as a Cost-Effectiveness Threshold (CET). 
The CET sets, on average, the maximum financial investment a 
public payer will commit to generate a unit of health (Cameron 
et al., 2018) and is typically used alongside other informa-
tion to inform decisions around resource allocation in health, 
particularly around the introduction of new treatments and 
benefits.
The use of CETs (and ICERs) is typically associated with a 
goal of health maximisation. They can also, however, be used in 
conjunction with other criteria. For instance, in Norway a CET 
was used to maximise both health together with a fair distri-
bution of health (Ottersen et al., 2016). While health system 
objectives might vary between jurisdictions, maximising health 
is one aspiration that we assume is widely shared within and 
across jurisdictions (Culyer, 2016).
There is still much confusion about the meaning and uses of 
the CET, how it should be calculated, and what constitutes ade-
quate evidence base for its formulation (Ochalek et al., 2015). 
There are three broad bases on which CETs that are used by public 
payers are set: willingness to pay (WTP), precedence and oppor-
tunity cost (for further discussion, see Santos et al., 2018 and 
Vallejo-Torres et al., 2016). However, a commonly used approach 
following none of the three bases is to set the CET at 1-3 times 
GDP per capita, including in Low and Middle-Income Coun-
tries (LMICs). It is often attributed to the Commission on 
Macroeconomics, and was later adopted in the WHO guidelines on 
Choosing Interventions that are Cost Effective (WHO-CHOICE) 
(World Health Organization Commission on Macroeconom-
ics and Health, 2001). Using this approach, an intervention that 
averts one DALY for a cost less than GDP per capita is consid-
ered “very” cost effective, but an intervention could still count 
as cost-effective if the ICER did not exceed three times GDP per 
capita. One rationale behind the rule is that GDP per capita is a 
proxy for earnings (Robinson et al., 2017). In other words, if 
an intervention averts a DALY at less than one GDP per capita, 
then its return on investments in the wider economy (through 
increased labour productivity) would offset its implementation 
costs. Because of its simplicity of use and interpretation, the 1-3 
GDP threshold has gained much popularity in recent years. 
A recent review of cost-effectiveness analyses (CEA) found 
that 66% of published research studies between 2000 and 2015 
in LMICs used a GDP-based CET (Leech et al., 2018)i.
The 1-3 GDP per capita criterion in the Commission on 
Macroeconomics and Health report was, however, never intended 
to be used to determine CETs. It was to be used to value health 
in benefit-cost analyses (e.g. to make the case for resource allo-
cation to health as opposed to other sectors) (Robinson et al., 
2017). Moreover, GDP-based CETs have no direct relation to a 
country’s healthcare budget, technical capacity, population pref-
erences or social values (Marseille et al., 2015). Several experts 
have also shown that GDP-based CETs can lead to the adop-
tion of interventions that are not in practice locally affordable 
(Marseille et al., 2015). One may argue that there is no harm in 
casting the net wide by setting a high CET. This is false, how-
ever, because spending health resources inevitably creates oppor-
tunity costs. Health opportunity costs arise because resources 
committed to one intervention are no longer available to fund 
alternative, perhaps more cost-effective, interventions. As a 
result, allocating resources to an intervention that would not 
be included by reference to a more realistic CET can paradoxi-
cally result in a loss of health and increase in avoidable deaths, 
by displacing more health than it creates (Revill et al., 2018). 
Health opportunity costs are higher in LMICs because spending 
on the wrong interventions might deplete a country’s resources 
to pay for affordable and effective interventions. In stylized 
terms, in a country where a life could be saved by spending 
$1000 dollars, the misallocation of that same $1000 will cause 
a death.
These considerations have contributed to a growing unease 
with the use of GDP-based CETs, especially in LMICs, given 
how widely they are used in research (Leech et al., 2018). More 
recently, several experts, including some at the WHO where the 
practice has been referenced for decades, have advised against 
the use of GDP-based CETs as a sole decision rule (Bertram 
et al., 2016).
The retraction of the 1-3 GDP rule leaves a vacuum for policy-
makers and technical staff at a time when LMICs are aspir-
ing to Universal Health Coverage (UHC) and making decisions 
that will set the path of health policy and spending for decades 
to come. As others have observed (Global Burden of Disease 
Health Financing Collaborator Network, 2019), mobilising addi-
tional resources for health is a lengthy and challenging proc-
ess; making decision rules such as CETs to ensure adequate 
spending all the more important. An appropriately set CET could 
support the realisation of the most generous possible form of 
UHC by ensuring that existing resources are primarily directed 
toward cost-effective interventions.
In addition, countries have been encouraged to develop 
in-country capacity and institutions to support the use of HTA 
in decision-making. This is fully supported by the WHO and is 
reflected in the World Health Assembly WHA67/23 resolution 
(World Health Organisation, 2014). In several countries (e.g. 
Indonesia, Kenya, Ghana, South Africa, India and the Philippines), 
plans to institutionalise HTA or set up HTA committees were 
announced in official communications (Addo, 2019; Authority of 
the Republic of Kenya, 2018; Congress of the Philippines, 2019; 
Ministry of Health and Family Welfare, 2019; Sharma et al., 
2020). These committees and agencies are likely to include 
CETs as part of their decision-making processes.i There is no published review of the use of CETs by decision-makers.
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The theory of CETs is discussed elsewhere and reviews docu-
ment how countries with existing CETs have defined them 
(Cameron et al., 2018; Santos et al., 2018; Thokala et al., 2018; 
Vallejo-Torres et al., 2016). Shortcomings of existing approaches 
to CETs, not exclusively focusing on GDP-based CETs, have 
also been discussed (Bertram et al., 2016; Marseille et al., 
2015; Newall et al., 2014; Vallejo-Torres et al., 2016). What 
is missing is the creation of practical alternatives to the use of 
GDP-based thresholds. This article seeks to address this gap 
by offering five practical options for developing locally rel-
evant CETs (i.e. ones that are informed by local data) or uti-
lising evidence (existing, complementary to CEA) to support 
decision-makers facing urgent resource allocation decisions.
The paper builds on a consultation between academics, coun-
try technical staff and global donors from high, middle, and 
low income countries (although not representative), organised 
by the International Decision Support Initiative (Secretariat 
based in the UK), Centre for Health Economics (University of 
York) and the Health Intervention and Technology Assessment 
Program (Thailand), at the Rockefeller Foundation Bellagio 
Centre between December 3-7, 2018. The group spent three 
and a half days discussing the role of CETs in achieving UHC 
in LMICsii. Our conversation focussed on supply-side approaches. 
There is one major reason for this. The willingness-to-pay 
approach raises question of whose willingness matters, a politi-
cal matter on which we do not feel able to advise, and can also 
lead to the use of aspirational CETs that are not connected to 
budget constraints or health opportunity costs. The supply-
side approach by contrast is focussed on the resources avail-
able, how they are currently used, and what is most likely to be 
sacrificed when they are used in one way rather than another. 
These are concrete matters that decision-makers face on a daily 
basis.
During this meeting, our group collectively defined five options 
that can replace the GDP based threshold (in the absence of 
a formal CET) when decision-makers are faced with a new 
intervention that they need to consider. We have ordered the 
options from the least to the most resource and data intensive, 
with option 5 being a within-country empirical estimation of 
supply-side CET that reflects health opportunity costs. The 
options are not mutually exclusive: it is possible to combine 
several approaches according to context and need.
Option 1. Use existing estimates of national health 
opportunity cost thresholds derived from cross-
country data
Two recent contributions (Ochalek et al., 2018; Woods et al., 
2016) provide estimates of health opportunity costs (i.e. what is 
given up as a consequence of introducing an intervention), coun-
try by country, for a number of LMICs. Woods et al. (2016) 
extrapolate health opportunity costs in LMICs from UK esti-
mates produced by Claxton et al. (2015) by applying data on 
the income elasticity of the value of health to generate ranges of 
cost per QALY gained estimates in LMICs. Ochalek et al. 
(2018) expand country estimates from Bokhari et al. (2007) on 
the effect of changes in health expenditure on health outcomes 
and, following Claxton et al. (2015), apply country-specific 
data on health expenditure, epidemiology and demography to 
calculate a range of cost per DALY averted thresholds esti-
mates in LMICs. Country by country estimates are available 
in their supplemental materials. To date, those two studies are 
the best attempts to estimate health opportunity costs using 
cross-country data sources, despite methodological caveatsiii.
Although adopting different approaches, both Woods et al. 
(2016) and Ochalek et al. (2018) estimate CETs averagingiv 
roughly half of GDP per capita, albeit with a substantial range. 
On this basis, if a GDP based rule is applied, it would prob-
ably be a secure rule to deem as cost-ineffective all interven-
tions averting 1 DALY at more than 1 GDP per capita. Half of 
GDP per capita is more in accord with countries’ realities than 
the 1-3 GDP per capita, and could be used as an interim rule of 
thumb rather than the 1-3 GDP rule. A handful of recent papers 
have already started using half of GDP per capitav. Francke et al. 
(2016) estimated the cost-effectiveness of diagnostic of HIV 
infection in early infancy in South Africa, and based on ‘emerg-
ing literature’, used a CET of half of GDP per capita. Other stud-
ies also used such a CET, although none provided a justification 
for doing so (Bilcke et al., 2019; Campos et al., 2018; Mezei 
et al., 2018). Finally, half of GDP per capita was also refer-
enced in the Disease Control Priorities 3 (DCP3) as an exam-
ple CET in highly resource constrained countries (Watkins 
et al., 2017). Half of GDP per capita will lead to underestimat-
ing or overestimating health opportunity costs in roughly half of 
LMICs (Ochalek et al., 2020b).
Option 2. Use existing evidence from other 
settings
Short cuts can sometimes offer an informed way forward when 
decision-makers are uncertain about appropriate methodologies 
or lack the necessary skill and evidence base for more sophis-
ticated procedures. One shortcut could be to look at evidence 
elsewhere by asking the following questions:
•฀฀฀฀Have regulatory authorities such as the Food and Drug 
Administration licensed this product and for which 
indication? This question can first identify ‘wasted buys’ 
(i.e. interventions that have a harmful or non-beneficial 
effect for a patient) if the intervention under considera-
tion was not licensed (for the right indication), without 
identifying a CET or conducting a CEA. For instance, 
a review of the Romanian procurement decisions found 
ii For more information about the meeting and its participants, go to: https://www.
idsihealth.org/blog/developing-cost-effectiveness-thresholds-to-support-univer-
sal-health-coverage/
iii Data limitations are acknowledged in the two papers and use of strong 
assumptions.
iv Unweighted average
v In preparing this commentary, we searched the cost-effectiveness analyses con-
ducted in LMICs in the last five years using the TUFTS database. Conclusions 
from this search will be subject to a different piece focusing on the use of CETs 
in the past five years (forthcoming).
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that bevacizumab was being used for the treatment of 
metastatic breast cancer, despite having been withdrawn 
from FDA approval for this indication (Lopert et al., 2013; 
US Food & Drug Administration, 2011). Other agen-
cies in charge of ensuring the safety, efficacy and security 
of drugs and products can be considered.
•฀฀฀฀Was this rejected for funding elsewhere? The National 
Institute for Health and Care Excellence (NICE) in 
the UK publishes its technology appraisal guidance, 
which contains information on the technology under 
consideration and the accompanying recommendations. 
NICE’s negative recommendations can be a useful start-
ing point since interventions not recommended in a 
high-income country are very unlikely to be appropriate 
choices in LMICs unless it was thought that the United 
Kingdom’s health system and financial capacity is very 
different from the country under consideration. On the 
other hand, a NICE positive recommendation is not to 
be followed slavishly in LMICs, because of differential 
health opportunity costs.
CEA estimates are not always transferrable across settings, 
and there is little guidance on how to make decisions about 
suitability of estimates in a local context (Drummond et al., 
2009). Nonetheless, if an intervention was found not to be 
cost-effective in a high-income setting, then it is unlikely to be 
cost-effective in an LMIC; and it would need important differ-
ences in disease epidemiology, intervention costs or health state 
preferences to warrant adoption in an LMICs.
Option 3. ICERs and budget impact to inform cost-
effectiveness and affordability
Budget impact analyses (BIA) can also support decision-makers 
in determining whether an intervention is affordable to the 
country (Bilinski et al., 2017). BIA is a method of assessing 
predicted short-term changes in expenditure were a new inter-
vention were introduced. It reflects not only the total cost of its 
introduction, but also the coverage and uptake rates, as well as 
potential new health costs (or savings) (Sullivan et al., 2014). 
There is often a disconnect between the cost-effectiveness of an 
intervention, and its affordability to a country (Bilinski et al., 2017; 
Howdon et al., 2019; Lomas, 2019; Wiseman et al., 2016). Pre-
senting BIA alongside CEA can ensure that decision-makers 
can anticipate the resource implications of a new interven-
tion for the allocation of their budget (Mohara et al., 2012). For 
instance, treatment of Hepatitis C was found to be cost-effective 
in many settings, but providing universal access to all eligible 
patients would have significant resource implications, even in 
middle-income countries (Urrutia et al., 2016). In the United 
Kingdom, treatment of Hepatitis C was found to be cost-effective 
but this decision was found to be controversial due its 
budget impact (Lomas et al., 2018).
Even in countries where a CET is used to inform policy, there 
is growing consideration of BIA. In Thailand, the ICER is pre-
sented alongside budget impact. For instance, the inclusion of 
Imiglucerase for Gaucher disease type 1 was approved due to 
the low budget impact, equity concerns and disease severity 
(terminal condition) even though the treatment was well above 
the Thai CET (Leelahavarong, 2019). Since 2017, budget impact 
for the first three years of use is assessed in the United-Kingdom. 
If it exceeds a certain threshold for the entire National Health 
Service (currently £20 million), a phased implementation or 
price negotiation with manufacturers is initiated (National 
Institute for Health and Care Excellence, 2018). However, 
Bilinski et al. (2017) report that fewer than 3% of the 384 pub-
lished CEA included in their review contained a full report 
of BIA.
Option 4. A league table for Health Benefits 
Package design
A league table is a list of health interventions in order of their 
ICER. It can be a useful approach to allow decision-makers to 
appraise a wide range of interventions in one summary table.
When considering a new inclusion to an existing Health Ben-
efits Package (HBP), a league table can be used to identify the 
least cost-effective intervention that has been funded under the 
HBP, which can serve as a benchmark to infer what the maxi-
mum investment the country was willing to commit to produc-
ing an additional unit of health when developing the HBP – or to 
initiate more detailed evaluation of its likely cost-effectiveness. 
In other words, the league table helps identify a proxy of the 
shadow CET. This approach can be appropriate if an exist-
ing package of services is available in the country and ICERs 
can be derived for a reasonable number of the interventions 
included in this package. Using this method, decision-makers 
could gain confidence that a new entrant would not be 
included unless it produced more health benefit than the least 
cost-effective intervention already covered.
On the other hand, when developing an HBP de novo, a 
league table can also be used to set a CET when combined 
with data on coverage and utilisation. For this, the budget 
envelope will need to be defined from the onset. This may 
not be easy, especially in countries where contributions from 
external partners is significant. For instance, in a study in 
Malawi from Ochalek et al. (2018), the authors highlight that 
donor funds (often off budget, disbursed through condition-
alities) make up 70% of total health expenditure. This creates 
uncertainties on how the budget line is set (the authors calcu-
late the budget line considering all funding, regardless of the 
source).
In this option, the budget line determines the CET: a league 
table is constructed in descending order of cost-effectiveness, 
and estimates of utilisation are used to calculate the budget 
impact for each intervention. Culyer (2016) uses a metaphor 
of a bookshelf of healthcare interventions, in which each book is 
ranked according to its height (i.e., its effectiveness-cost ratio) 
and the thickness of the book represents the cost of provid-
ing the intervention (i.e., the budget impact). The threshold cor-
responds to the least cost-effective intervention affordable to the 
country before the (fixed) budget is exhausted. This approach 
was reported to be implemented in Oregon’s Medicaid scheme 
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in the 1990s to define health benefits (although a review 
(Tengs et al., 1996) later showed that there was no correla-
tion between the final benefits list and the economic literature or 
Oregon’s own cost-effectiveness data).
While the data requirements for this option appear be high to 
some, they can be much reduced by using expert opinion and 
international evidence to identify a narrower range of likely 
candidates for more detailed evaluation. This enables deci-
sion makers to focus their attention on a manageable number of 
possible interventions together with their relevant uncer-
tainties. One challenge in LMICs is the low availability of 
evidence on cost-effectiveness, as well as differences in the meth-
odological specifications employed in studies (Drummond et al., 
1993; Mauskopf et al., 2003). Comparing them usefully requires 
local epidemiological and economic skills. However, there are 
several global sources which can be compiled to inform coun-
try level estimates: DCP3, the TUFTS GHCEA Registry and 
WHO-CHOICE. These sources were used by the Ochalek et al. 
(2018) study, although important data gaps remained and were 
highlighted as a limitation to the study. In Ethiopia, a simi-
lar approach was used to develop the Essential Health Services 
Package (Ministry of Health Ethiopia, 2019). It is worth not-
ing that WHO-CHOICE present average cost-effectiveness ratios 
(ACERs) instead of incremental ones (Arnold et al., 2019). This 
is sometimes raised as a concern because average cost-effectiveness 
ratios compare interventions to a doing nothing scenario, 
which is only very rarely an appropriate comparator (O’Day & 
Campbell, 2016).
Option 5. Estimating a health opportunity cost CET 
using within-country data
Notwithstanding the different approaches to defining a CET, 
this group found that defining CETs based on health opportu-
nity costs using within-country data was particularly suitable in 
LMICs given the high opportunity costs created by severe 
budget constraints. However, each country may want to develop 
its own national CET, relevant to their own situation.
Relying on health opportunity cost estimates makes it 
possible to estimate whether the health gains produced by an 
intervention are greater than the health lost from displacing 
other interventions in other parts of the health system (Claxton 
et al., 2015). This approach derives from the goal of health 
maximisation. Where health must be sacrificed to improve dis-
tributional outcomes (or to meet goals other than health max-
imisation), a health opportunity cost CET can help quantifying 
the trade-off. Unlike the WTP method, which bears no link to 
public budgets, the health opportunity cost method calibrates 
the CET against the reality of local budget constraints (Brouwer 
et al., 2019; Leech et al., 2018).
The seminal works of Claxton et al. (2015) in the UK pio-
neered the estimation of health opportunity costs CETs. They 
used a very detailed programme budgeting data from the 
English National Health Service (NHS) to estimate a health 
opportunity cost CET, which was much lower (£12,936) than 
the one then applied (£20,000-30,000 and up to £100,000 in 
certain cases).
Attempts to apply a similar estimation framework have been 
made in China, Indonesia, India and the Republic of South 
Africa (Edoka & Stacey, 2020; Ochalek et al., 2020), although 
with different methods and data (given the paucity of the latter 
in LMICs). These estimates have two parts: estimating the elas-
ticities of health outcomes with regard to health expenditure 
using an econometric analysis, and translating the elasticity 
estimates to health opportunity cost thresholds. In order to esti-
mate health spending elasticities, data on health expenditure and 
health outcomes (e.g. mortality rates, DALYs or QALYs – and 
ideally age and gender specific) at a low level of aggregation 
(e.g. local health authorities or districts and provinces) is 
required. Ideally, these data will need to be collected across 
several time periods/years. Furthermore, the estimation of health 
spending elasticities could be strengthened if controlling for poten-
tial confounders (e.g. poverty, literacy rate) and the application 
of robust estimation strategies to account for unobserved hetero-
geneity and reverse causality (Edoka, 2019). One such approach 
consists of using an instrumental variable (IV) (i.e. a variable 
that has no direct impact on the health outcome but indirectly, 
through its impact on health expenditure). IVs should be selected 
by researchers to fit the local context. One example in the UK 
has been the use of the ‘funding rule’: local jurisdictions in 
the UK receive a share of the total budget based on local char-
acteristics, however, the funding rule is revised periodically 
and this change creates exogenous changes in local funding 
and generates data for econometric estimation of elasticities 
(Claxton et al., 2018). 
Elasticities will need to be translated into population esti-
mates of cost per DALY averted or QALY gained. If research-
ers estimated elasticities using mortality data, then those must 
be converted into QALYs or DALYs using additional assump-
tions. This requires data on the age and gender structure of the 
population as well as the morbidity burden of disease. It is worth 
noting that if the elasticities are estimated from the subset of 
the population (e.g. children), they will need to be extrapolated 
for the whole population.
There are several sources of uncertainty attaching to this 
approach, as there are to other approaches. Given a shortage of 
vital population statistics, health outcomes are often drawn from 
survey data, which come with their own shortcomings. Moreover, 
data on health expenditure is often incomplete (e.g. missing 
budget items), poorly collected (e.g. inconsistency in recording 
practice) and unavailable at a low level of aggregation or across 
several years. There might be uncertainty stemming from the 
methods employed (e.g. use of an appropriate instrumental 
variable).
Discussion
Setting priorities is more than ever before seen as a pre-requisite 
for achieving global development goals and UHC (Wiseman 
et al., 2016). This prerequisite was recognised at the United 
Nations High-Level Meeting on UHC in 2019 (United Nations 
General Assembly, 2019). There is now a push for using HTA 
across the world to drive more efficient resource allocation in 
health. Addressing the vacuum left by the abandonment of the 
1–3 times GDP per capita CET has therefore become central to 
determining what services or interventions will be included 
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or excluded within the UHC agenda. In addition, a CET or 
clear decision rule can signal maturity in resource alloca-
tion practices for the health budget to Treasuries or Ministry 
of Finance. This may support further investments in the health 
sector, especially in LMICs where health receives low priority 
within the broader government budgeting process.
This article lays out five alternatives to GDP-based CETs for 
decision-makers faced with urgent resource allocation deci-
sions, building from our meeting bringing together a selected 
group of practitioners and researchers. Estimating a health oppor-
tunity cost CET using local data is the long-run solution for 
LMICs since it will explicitly link CETs to budget constraints 
and help articulate the trade-offs that inevitably arise in cover-
age decisions. Stakeholders should understand how a CET can 
be estimated, what the possible alternatives are, and be able to 
assess the adequacy of the arrangements in, or proposed for, 
their country. This will require engagement and communication 
from the onset.
While an empirically estimated supply-side CET using local 
data, should be the long term aim for all countries, the other four 
suggestions provide LMICs with tools to structure what is often 
a difficult ad hoc conversation on value for money and afford-
ability. This intermediate step would represent a significant 
improvement on current practice and the first four options require 
no additional or only modest additional resources. In combi-
nation, these suggestions can help form deliberative processes 
that are as evidence-based as possible and that face explicitly 
up to the complexity of the choices faced by decision-makers 
(Baltussen et al., 2016; Chalkidou et al., 2016).
The dangers of applying thresholds that are set too high have 
been discussed widely elsewhere (Bertram et al., 2016; Leech 
et al., 2018; Marseille et al., 2015). It is likely that our proposed 
approach would lead to more conservative CETs compared to the 
1–3 times GDP per capita rule. For this reason, it is worth con-
sidering what the implications and risks of under-estimating 
the CET would be. The first obvious consequence would be 
that cost-effective interventions would be mistakenly ruled 
out, causing a loss of health at the population level relative to 
what would have been possible if resources were fully allo-
cated to cost-effective interventions. Some have also argued 
that a low CET reduces innovation by discouraging manufac-
turers from seeking to develop new products. Finally, it may 
be thought that a more conservative CET is incompatible with 
other social objectives of the healthcare system that do not align 
or may even conflict with the goal of health maximisation (e.g. 
priority to the poor or more broadly equity).
These concerns need to be addressed seriously. Further research 
should help to make more reliable any estimates of a local 
CET based on health opportunity costs. Further work on the 
LMIC estimates of Woods et al. (2016) and Ochalek et al. 
(2018) would enable better methods and reduce some of the 
uncertainty and data challenges. Moreover, it is worth not-
ing that CETs are not only used as a simple inclusion/exclusion 
rule, but also as a basis for price negotiation with manufacturers. 
In Thailand, economic evaluation has successfully been used to 
bring down drug prices: for instance, the price of Tenofovir was 
cut down more than two third from the original to the negotiated 
price using the CET (Teerawattananon et al., 2014).
On innovation, there is growing evidence that the vast major-
ity of new products approved for use are only marginal improve-
ments on existing ones, and new market introductions are 
often priced well above the existing thresholds, especially in 
LMICs. For example, a discussion of cancer drugs highlights 
that new introductions are often ‘prohibitively expensive’ and 
therefore unaffordable for publicly funded systems in LMICs 
(Gyawali & Sullivan, 2017). Recent studies have also pointed 
to the fact that high CETs created perverse incentives on prices, 
as manufacturers can use the CET to calculate a maximum ceil-
ing price for their products to be accepted (Gronde et al., 
2017). There is no evidence that high aspirational CETs encour-
aged innovation or access to novel treatments (Claxton et al., 
2009), so the disincentive, if that is what it is, of lower CETs may 
be similarly unimportant. More important is for LMIC countries 
individually or collectively to identify the kinds of innovation 
they would most like to see and then to engage in a discussion 
with manufacturers and other stakeholders as to suitable incen-
tives (or removal of disincentives). The inclusion of social 
objectives other than health maximization, like equity, posi-
tive discrimination, managerial capacities at various healthcare 
delivery levels, is independent of the level at which a threshold 
is set, and should be discussed alongside cost-effectiveness in 
any HTA framework (Cookson, 2016). More realistic CETs 
might well be intrinsically more equitable than high ones because 
the inclusion of wasted buys leads to crowding out of resources 
that would otherwise be spent on cost-effective services, 
usually benefitting the poor.
This piece has provided a menu of options that can be used as 
an alternative to GDP based thresholds. The primary audience 
for this piece has been national decision-makers, but our recom-
mendations have ramifications for the global health commu-
nity. Development partners (DPs) should consider supporting 
countries in the challenging estimation of locally relevant CETs, 
working with research institutions with this expertise. The use 
of CETs to inform resource decisions by DPs has not been 
widely researched (Drake, 2014; (Morton et al., 2018). Should 
DPs use a single global threshold (as most countries do) or rely 
on country-specific thresholds, whether estimated by them or 
the countries in question? This is a contentious issue. Locally 
estimated CETs reflect the local health opportunity costs, 
which will be important for countries in transition with increas-
ing co-financing from domestic resources (Silverman, 2018). 
This will raise consistency issues if different payers adopt dif-
ferent CETs, or ones that conflict with those preferred by 
recipient countries. For example, the Global Fund affords pri-
ority to the fight against AIDS, Tuberculosis and Malaria, but 
recipient countries may apply different threshold values to the 
same programs. On the other hand, using country thresholds 
would mean that DPs would apply different decision rules to dif-
ferent recipient countries. There is a universal inverse relation 
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between GDP per capita and opportunity cost-based CETs, 
so using national thresholds may signal a mean that an inter-
vention covered in a middle income country may not be cov-
ered in low income one, which may be politically challenging. 
Conversely, it may also signal to DPs that spending in low 
income countries is more impactful, as a DALY averted or QALY 
gain can be realised at lower cost. The matter plainly needs 
further thought and investigation.
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